The deepening understanding of the transcriptional, epigenetic, and metabolic characteristics that drive and maintain different exhaustion states of CD8+ T cells provide insights for designing immunotherapies that can reduce adverse events and improve tumor control. This evidence concerns the gene CD8A and neoplasm.